Outpatient treatment of worsening heart failure with intravenous diuretics: first results from a multicentre 2-year experience

被引:3
作者
Wierda, Eric [1 ]
van Maarschalkerwaart, Willemijn W. A. [2 ]
van Seumeren, Esther [2 ]
Dickhoff, Cathelijne [1 ]
Montanus, Irina [2 ]
de Boer, Dominique [1 ]
Kop, Esther [2 ]
de Mol, Bas A. J. M. [3 ]
Schroeder-Tanka, Jutta M. [2 ]
van Heerbeek, Loek [2 ]
机构
[1] Dijklander Ziekenhuis, Dept Cardiol, Hoorn, Netherlands
[2] OLVG, Dept Cardiol, Amsterdam, Netherlands
[3] Univ Amsterdam, Dept Cardiothorac Surg, Med Ctr, Amsterdam, Netherlands
来源
ESC HEART FAILURE | 2023年 / 10卷 / 01期
关键词
Outpatient treatment; Diuretics; Heart failure; Worsening heart failure; THERAPY;
D O I
10.1002/ehf2.14168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The aim of this study is to examine the safety and efficacy of outpatient treatment of worsening heart failure (WHF) with intravenous diuretics. Methods and results This is a multicentre retrospective observational research study. Patients with all types of heart failure (HF) were included: heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF). Patients included in this study were 18 years or older, had symptoms of WHF, had weight gain of more than 2 kg, and were not responding to uptitrating of oral diuretic therapy. Patients were treated for one or more days at the outpatient department with administration of intravenous loop diuretics with or without a bolus. In this study, 259 patients were included (mean age of 76 years, mean left ventricular ejection fraction of 41%). Rehospitalization rates for HF were 30.5% and 53.3%, respectively, at 30 days and 1 year. All-cause mortality was 5.8% and 26.3%, respectively, at 30 days and 1 year. Rehospitalization rates for HF and all-cause mortality were highest in patients with HFrEF. In a total of 322 individual outpatient treatments with intravenous diuretics, only one adverse event was registered. Conclusions Outpatient treatment with intravenous diuretics of patients with WHF is a safe alternative strategy compared with the same treatment in hospitalized patients. However, only non-randomized data are available and rehospitalization rates for this group with WHF are high. No data are available on the best selection criteria and the cost-effectiveness of outpatient treatment with intravenous diuretics.
引用
收藏
页码:594 / 600
页数:7
相关论文
共 26 条
  • [11] Nephrocalcinosis in full-term infants receiving furosemide treatment for congestive heart failure: a study of the incidence and 2-year follow up
    Saarela, T
    Lanning, P
    Koivisto, M
    Paavilainen, T
    EUROPEAN JOURNAL OF PEDIATRICS, 1999, 158 (08) : 668 - 672
  • [12] Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients The ROADMAP Study 2-Year Results
    Starling, Randall C.
    Estep, Jerry D.
    Horstmanshof, Douglas A.
    Milano, Carmelo A.
    Stehlik, Josef
    Shah, Keyur B.
    Bruckner, Brian A.
    Lee, Sangjin
    Long, James W.
    Selzman, Craig H.
    Kasirajan, Vigneshwar
    Haas, Donald C.
    Boyle, Andrew J.
    Chuang, Joyce
    Farrar, David J.
    Rogers, Joseph G.
    JACC-HEART FAILURE, 2017, 5 (07) : 518 - 527
  • [13] Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure -: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study
    Klein, L
    O'Connor, CM
    Leimberger, JD
    Gattis-Stough, W
    Piña, IL
    Felker, M
    Adams, KF
    Califf, RM
    Gheorghiade, M
    CIRCULATION, 2005, 111 (19) : 2454 - 2460
  • [14] One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure
    Mann, Douglas L.
    Lee, Randall J.
    Coats, Andrew J. S.
    Neagoe, Gheorghe
    Dragomir, Dinu
    Pusineri, Enrico
    Piredda, Massimo
    Bettari, Luca
    Kirwan, Bridget-Anne
    Dowling, Robert
    Volterrani, Maurizio
    Solomon, Scott D.
    Sabbah, Hani N.
    Hinson, Andy
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (03) : 314 - 325
  • [15] Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
    Armentaro, Giuseppe
    D'Arrigo, Graziella
    Magurno, Marcello
    Toscani, Alfredo F.
    Condoleo, Valentino
    Miceli, Sofia
    Cassano, Velia
    Maio, Raffaele
    Arturi, Franco
    Tripepi, Giovanni
    Sesti, Giorgio
    Sciacqua, Angela
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [16] A Novel Balanced Dual Vasopressin V1a/V2 Receptor Antagonist for Treatment of Congestive Heart Failure: Results From a First-in-Man Study
    Pimenta, Eduardo
    Jensen, Markus
    Jung, David
    Lobmeyer, Maximilian
    Schmitt, Walter
    Schaumann, Frank
    Boxnick, Stefanie
    Truebel, Hubert
    CIRCULATION, 2017, 136
  • [17] Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure –1 year results from the Ce mark trial
    Thomas Krabatsch
    Ivan Netuka
    Jan D. Schmitto
    Daniel Zimpfer
    Jens Garbade
    Vivek Rao
    Michiel Morshuis
    Friedhelm Beyersdorf
    Silvana Marasco
    Laura Damme
    Yuriy Pya
    Journal of Cardiothoracic Surgery, 12
  • [18] Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure-1 year results from the Ce mark trial
    Krabatsch, Thomas
    Netuka, Ivan
    Schmitto, Jan D.
    Zimpfer, Daniel
    Garbade, Jens
    Rao, Vivek
    Morshuis, Michiel
    Beyersdorf, Friedhelm
    Marasco, Silvana
    Damme, Laura
    Pya, Yuriy
    JOURNAL OF CARDIOTHORACIC SURGERY, 2017, 12
  • [19] First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: Mid-term safety and efficacy results from a multicenter study
    Pappone, C
    Augello, G
    Rosanio, S
    Vicedomini, G
    Santinelli, V
    Romano, M
    Agricola, E
    Maggi, F
    Buchmayr, G
    Moretti, G
    Mika, Y
    Ben-Haim, SA
    Wolzt, M
    Stix, G
    Schmidinger, H
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2004, 15 (04) : 418 - 427
  • [20] Is elevation of N-terminal pro-B-type natriuretic peptide at discharge associated with 2-year composite endpoint of all-cause mortality and heart failure hospitalisation after transcatheter aortic valve implantation? Insights from a multicentre prospective OCEAN-TAVI registry in Japan
    Mizutani, Kazuki
    Hara, Masahiko
    Nakao, Mana
    Okai, Tsukasa
    Kajio, Keiko
    Murakami, Takashi
    Shibata, Toshihiko
    Yoshiyama, Minoru
    Naganuma, Toru
    Yamanaka, Futoshi
    Higashimori, Akihiro
    Tada, Norio
    Takagi, Kensuke
    Araki, Motoharu
    Ueno, Hiroshi
    Tabata, Minoru
    Shirai, Shinichi
    Watanabe, Yusuke
    Yamamoto, Masanori
    Hayashida, Kentaro
    BMJ OPEN, 2018, 8 (08):